Key Highlights

  • Oculis reported a third-quarter net loss of CHF 18.2 million.
  • Research and development expense rose to CHF 15.1 million from CHF 14.1 million.
  • CHF 210.3 million in cash and investments funds operations into the second half of 2029.
  • PREDICT-1 dry eye topline data is expected around year-end.

Oculis Holding AG (NASDAQ:OCS) is spending more as it pushes two late-stage programs toward key milestones. Its third-quarter 2026 report showed Research and Development expense rising to CHF 15.1 million and general and administrative expense climbing to CHF 8.6 million, contributing to what market data described as a wider quarterly loss. With topline data from the PREDICT-1 dry eye trial expected around year-end and an R&D Day scheduled for December 8, the company's cost trajectory may be watched alongside its clinical progress.

Latest Company Context

Oculis reported a third-quarter net loss of CHF 18.2 million. R&D expense rose to CHF 15.1 million ($18.5 million) from CHF 14.1 million a year earlier, while G&A increased to CHF 8.6 million ($10.6 million) from CHF 6.4 million, roughly a one-third increase. Combined R&D and G&A reached CHF 23.7 million in the quarter, up from CHF 20.5 million a year earlier.

For the nine months, the net loss was CHF 57.1 million ($71.7 million), down from CHF 75.4 million, but the company attributed that improvement mainly to a Fair Value gain on Warrant liabilities rather than lower operating costs. Nine-month R&D and G&A totaled CHF 44.4 million and CHF 25.1 million, respectively. Cash and short-term investments were CHF 210.3 million ($252.0 million) at September 30, 2026, which the company said funds operations into the second half of 2029.

Key Business and index Drivers

The spending increase reflects a pipeline that has broadened into neurology. Oculis acquired rights to privosegtor and an early-stage candidate from Accure Therapeutics and is advancing the PIONEER-1 trial in optic neuritis in the U.S. and Europe, while preparing for an expected fourth-quarter IND clearance in acute multiple sclerosis relapses. It has also added senior neurology talent, including Chief Scientific Officer Björn Tackenberg. Licaminlimab's PREDICT-1 trial completed randomization with 176 patients, about two-thirds carrying the TNFR1 genetic variant.

CEO Riad Sherif said licaminlimab "could potentially become the first precision medicine in ophthalmology," a claim PREDICT-1 is designed to test. Higher G&A may partly reflect this organizational buildout. Because non-cash items such as warrant revaluations can swing the bottom line, operating expenses may give a clearer view of underlying cash burn. If sustained, expenses rising faster than in prior periods could gradually compress the runway.

What Investors Should Watch

Several dated events could shape the expense outlook. This month the company presented at the Guggenheim (November 9-11) and Stifel (November 10-12) conferences and the LifeSci and Sofinnova summit in London on November 16. Oculis is scheduled to present at the Piper Sandler Healthcare Conference on December 1-3 and will host its R&D Day on December 8 at the St. Regis New York, with presentations on PREDICT-1 and the privosegtor roadmap.

Topline PREDICT-1 results are anticipated around year-end, and the company plans to attend the J.P. Morgan Healthcare Conference on January 11-14, 2027. Investors may look for any 2027 spending guidance, the cost of a potential MS relapse trial, and whether the runway into the second half of 2029 is reaffirmed after these milestones. PREDICT-1 outcomes could influence how resources are allocated across programs.

Costs Rise Ahead of Readouts

Oculis's third quarter showed rising operating costs as it expands into neuro-ophthalmology and neurology while awaiting a pivotal dry eye readout. A sizable cash position offers flexibility, but the headline nine-month improvement owed more to warrant accounting than to spending discipline. Upcoming data and R&D Day disclosures could clarify whether higher Investment translates into meaningful clinical progress for the company's two lead programs. Investors may weigh how quickly the quarterly cost base keeps rising against the runway the company has outlined.